FORT COLLINS, Colo., Jan. 22, 2026 /PRNewswire/ — PhotonPharma Inc., a leader in autologous cancer immunotherapies developing Innocell™ for stage III/IV ovarianFORT COLLINS, Colo., Jan. 22, 2026 /PRNewswire/ — PhotonPharma Inc., a leader in autologous cancer immunotherapies developing Innocell™ for stage III/IV ovarian

PhotonPharma Inc. Appoints Vaccine Innovation Leader William Warren, Ph.D. to Board of Directors

4 min read

FORT COLLINS, Colo., Jan. 22, 2026 /PRNewswire/ — PhotonPharma Inc., a leader in autologous cancer immunotherapies developing Innocell™ for stage III/IV ovarian cancer, today announced the appointment of William Warren, Ph.D., to its Board of Directors, effective immediately. Dr. Warren brings over three decades of experience in biotechnology innovation, vaccine development, and successful entrepreneurship to guide PhotonPharma’s strategic initiatives and growth trajectory.

Dr. Warren most recently served in multiple senior leadership roles at Sanofi Vaccines R&D, including Head of Innovation, leading a virtual biotech to advance next-generation influenza vaccines, and Head of Global Antigen Design, where his group was responsible for antigen designs to advance projects, invigorate an innovative culture, and explore biology and technology interfaces. His leadership emphasized creating synergies between biology and technology interfaces to drive unexpected discoveries and advance critical vaccine programs.

“Dr. Warren’s unique combination of scientific excellence, entrepreneurial success, and industry leadership makes him an invaluable addition to our board,” said CEO/CSO Dr. Raymond Goodrich of PhotonPharma Inc. “His proven track record of translating innovative science into commercial success, coupled with his deep understanding of both startup and large pharma environments, will be instrumental as we advance our pipeline and scale our operations.”

Prior to Sanofi, Dr. Warren demonstrated exceptional entrepreneurial acumen as CEO and co-founder of VaxDesign Corporation, which he successfully led through its acquisition by Sanofi in 2010. He also co-founded nScrypt Inc., a company specializing in advanced 3D printing and bioprinting systems, demonstrating his ability to identify and capitalize on emerging technology platforms with significant medical applications. He was also a Managing Partner of Sciperio Inc., an innovative high-technology development company. 

Dr. Warren’s career includes pioneering work at the Defense Advanced Research Projects Agency (DARPA), where he served as program manager and helped establish the field of bioprinting tissue engineered constructs—a technology area that continues to transform regenerative medicine and drug development. His earlier role as Principal Member of Technical Staff at Sandia National Laboratories provided foundation in advanced materials and engineering sciences.

“I am excited to join PhotonPharma’s board at this pivotal time in the company’s evolution,” said Dr. Warren. “The company’s innovative approach to autologous cancer therapies represents exactly the kind of transformative technology that can address critical unmet medical needs. I look forward to leveraging my experience in building and scaling innovative biotechnology platforms to help PhotonPharma achieve its ambitious goals.”

Dr. Warren’s scientific credentials include Fellow designation from the American Institute for Medical and Biological Engineering (AIMBE), recognition as a distinguished alumnus of Pennsylvania State University, and authorship of over 200 peer-reviewed publications. His research impact is evidenced by papers ranked in the top 20 most cited in the Journal of Applied Physics and top 50 in Applied Physics Letters, along with more than two dozen patents or patent applications.

Dr. Warren holds both B.Sc. Honors and Ph.D. degrees in Engineering Science from The Pennsylvania State University. He currently serves as a consultant and board member for various biotechnology and not-for-profit organizations, bringing valuable cross-sector insights to his board service.

About PhotonPharma Inc.

PhotonPharma is dedicated to developing innovative autologous cancer therapies that leverage the body’s immune system to fight disease. With a focus on personalized medicine, the company’s lead product, Innocell™, aims to provide a safe and effective therapy for a wide range of solid organ tumors. In February 2024, PhotonPharma received FDA clearance for the company’s first Phase 1 study in the US: a first-in-human clinical study for stage III/IV ovarian cancer treatment with the investigational autologous vaccine therapy, Innocell™. The company has partnered with the City of Hope in Los Angeles to conduct the study. The Phase 1 clinical trial for Innocell™ will evaluate its safety, tolerability, and immune response indicators in patients with Stage III/IV ovarian cancer. Patient enrollment begins in January of 2026.

Contact Information:

Dr. Valerie Ray
Vice President of Operations
PhotonPharma Inc.
[email protected]
303-521-8401

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/photonpharma-inc-appoints-vaccine-innovation-leader-william-warren-phd-to-board-of-directors-302667466.html

SOURCE PhotonPharma Inc.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Galaxy Digital’s 2025 Loss: SOL Bear Market

Galaxy Digital’s 2025 Loss: SOL Bear Market

The post Galaxy Digital’s 2025 Loss: SOL Bear Market appeared on BitcoinEthereumNews.com. Galaxy Digital, a digital assets and artificial intelligence infrastructure
Share
BitcoinEthereumNews2026/02/04 09:49
FCA, crackdown on crypto

FCA, crackdown on crypto

The post FCA, crackdown on crypto appeared on BitcoinEthereumNews.com. The regulation of cryptocurrencies in the United Kingdom enters a decisive phase. The Financial Conduct Authority (FCA) has initiated a consultation to set minimum standards on transparency, consumer protection, and digital custody, in order to strengthen market confidence and ensure safer operations for exchanges, wallets, and crypto service providers. The consultation was published on May 2, 2025, and opened a public discussion on operational responsibilities and safeguarding requirements for digital assets (CoinDesk). The goal is to make the rules clearer without hindering the sector’s evolution. According to the data collected by our regulatory monitoring team, in the first weeks following the publication, the feedback received from professionals and operators focused mainly on custody, incident reporting, and insurance requirements. Industry analysts note that many responses require technical clarifications on multi-sig, asset segregation, and recovery protocols, as well as proposals to scale obligations based on the size of the operator. FCA Consultation: What’s on the Table The consultation document clarifies how to apply rules inspired by traditional finance to the crypto perimeter, balancing innovation, market integrity, and user protection. In this context, the goal is to introduce minimum standards for all firms under the supervision of the FCA, an essential step for a more transparent and secure sector, with measurable benefits for users. The proposed pillars Obligations towards consumers: assessment on the extension of the Consumer Duty – a requirement that mandates companies to provide “good outcomes” – to crypto services, with outcomes for users that are traceable and verifiable. Operational resilience: introduction of continuity requirements, incident response plans, and periodic testing to ensure the operational stability of platforms even in adverse scenarios. Financial Crime Prevention: strengthening AML/CFT measures through more stringent transaction monitoring and structured counterpart checks. Custody and safeguarding: definition of operational methods for the segregation of client assets, secure…
Share
BitcoinEthereumNews2025/09/18 05:40
HKMA Launches Fintech Blueprint with AI, DLT, Quantum and Cybersecurity Focus

HKMA Launches Fintech Blueprint with AI, DLT, Quantum and Cybersecurity Focus

The Hong Kong Monetary Authority (HKMA) published a Fintech Promotion Blueprint to support responsible innovation and fintech development in the banking sector.
Share
Fintechnews2026/02/04 10:20